| Identification | Back Directory | [Name]
Trityl candesartan | [CAS]
139481-72-4 | [Synonyms]
TRITYL CANDESARTAN
N-Trityl Candesartan
Triphenyl Candesartan
N-trimethylcandesartan
Trityl Candesartan (C9)
Candesartan Impurity 8
CANDESARTAN INTERMEDIATE A
Trityl candesartan USP/EP/BP
Candesartan N1-Trityl IMpurity
Candesartan Cilexetil Impurity 9
Candesartan Cilexetil Impurity 14
(1H)-Benzimidazole-7-carboxylicacid
Candesartan Cilexetil
Intermediate 5
TritylCandesartan,CandesartanCilexetil
TRITYL CANDESARTAN ( FOR CANDESARTAN CILEXETIL )
TritylCandesartan[CandesartabCilexetilIntermediates]
2-ethoxy-1-[[(2-(1-triphenylmethyl-1Htetrazol-5-yl)biphenyl-4-yl-)
2-Ethoxy-1-((2'-(1-trityl-1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-1H-benzo[d]imidazole-
2-Ethoxy-1-((2'-(1-trityl-1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-1H-benzo[d]imidazole-7-c
2-ETHOXY-1-[[(2-(1-TRIPHENYLMETHYL-1H-TETRAZOL-5-YL)BIPHENYL)METHYL] BENZIMIDAZOLE-7-CARBOXYLIC ACID
2-ethoxy-3-[[4-[2-[1-(triphenylmethyl)-5-tetrazolyl]phenyl]phenyl]methyl]-4-benzimidazolecarboxylic acid
2-ethoxy-1-[[(2'-(1-triphenylmethyl-1h-tetrazol-5-yl)biphenyl-4-yl)methyl]benzimidazole-7-carboxylic acid
2-Ethoxy-1-[[(2’-(1-triphenylmethyl-1H-tetrazol-5-yl)biphenyl-4-yl-)methyl]benzimidazole-7-carboxylicacid
2-Ethoxy-1-[[2-(2-Triphenylmethyl)-2H-Tetrazole-5-Yl](1,1-Biphenyl)-4-Yl]-Methyl]Benzimidazole-7-Carboylicacid
2-Ethoxy-1-((2'-(1-trityl-1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)Methyl)-1H-benzo[d]iMidazole-7-carboxylic acid
1H-benzimidazole-7-carboxylic acid, 1-[[2'-[1-(triphenylmethyl)-1H-tetrazol-5-yl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy
1H-Benzimidazole-7-carboxylic acid, 2-ethoxy-1-[[2'-[1-(triphenylmethyl)-1H-tetrazol-5-yl][1,1'-biphenyl]-4-yl]methyl]-
Trityl candesartan/2-Ethoxy-1-[[(2'-(1-triphenylmethyl-1H-tetrazol-5-yl)biphenyl-4-yl)methyl]benzimidazole-7-carboxylic acid
2-Ethoxy-1-((2'-(1-trityl-1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-1H-benzo[d]imidazole-7-carboxylic Acid
DISCONTINUED
(Trityl candesartan)2-Ethoxy-1-[[2-(2-Triphenyl Methyl)-2H-Tetrazole-5-YL](1,1-Biphenyl)-4-YL]Methyl]Benzimidazole-2-Carboxylic Acid
2-Ethoxy-1-[[2?-[2-(Triphenylmethyl)-2H-Tetrazol-5-
Yl][1,1?-Biphenyl]-4-Yl]Methyl]-1H-Benzimidazole-7- Carboxylic Acid [N-Trityl Candesartan] | [EINECS(EC#)]
604-140-9 | [Molecular Formula]
C43H34N6O3 | [MDL Number]
MFCD08436154 | [MOL File]
139481-72-4.mol | [Molecular Weight]
682.77 |
| Chemical Properties | Back Directory | [Melting point ]
163-165°C | [Boiling point ]
908.6±75.0 °C(Predicted) | [density ]
1.26±0.1 g/cm3(Predicted) | [storage temp. ]
Sealed in dry,2-8°C | [solubility ]
Chloroform (Slightly), Ethyl Acetate (Slightly), Methanol (Slightly, Heated) | [form ]
Solid | [pka]
2.06±0.10(Predicted) | [color ]
White to Off-White |
| Hazard Information | Back Directory | [Chemical Properties]
Off-White Solid | [Uses]
2-Ethoxy-1-((2''-(1-trityl-1H-tetrazol-5-yl)-[1,1''-biphenyl]-4-yl)methyl)-1H-benzo[d]imidazole-7-carboxylic Acid can be used as reagent/reactant in preparation of the anti-hypertensive drug candesartan cilexetil. | [Uses]
Candesartan analog as angiotensin II antagonist. | [Synthesis]
I. 1-((2'-(2H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2-ethoxy-1H-benzo[d]imidazole-7-carboxylic acid (10 kg) was added to the reaction kettle along with dichloromethane (100 kg), and cooled down to 15°C. The temperature of the reaction system was increased to 15°C by adding triethylamine (4.5 kg). Triethylamine (4.5 kg) was slowly added dropwise, and after the dropwise addition was completed, the temperature of the reaction system was raised to 23 °C. Triphenylchloromethane (7kg) was added in batches and after completion of addition, the reaction was maintained at 23°C for 3.5 hours. The reaction progress was monitored by TLC (unfolding agent: dichloromethane/methanol=10:1, v/v, Rf=0.78). After completion of the reaction, the pH of the system was adjusted to 5.4 by adding 0.1 mol/L HCl (30 L), then 5 L of 9 mol/L HCl was added slowly to pH=2.2, and the reaction was allowed to stand for stratification to separate the aqueous and organic layers. The organic layer (about 60 L) was washed with saturated saline, transferred to a reduced pressure distillation unit, and dichloromethane was recovered under reduced pressure. Ethanol (65L) was added to the residue, warmed to 45°C and stirred for 3 hours until a large amount of white solid precipitated. The heating was stopped, cooled to room temperature, filtered, the filter cake was washed with a small amount of ethanol, and dried at 50°C under normal pressure for 12 hours to obtain 2-ethoxy-1-((2'-(1-trityl-1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-1H-benzo[d]imidazole-7-carboxylic acid (white crystalline powder, 14.5 kg, yield 94.0%). | [References]
[1] Patent: CN105153124, 2018, B. Location in patent: Paragraph 0005; 0054; 0055; 0076; 0090
[2] Patent: WO2009/7986, 2009, A1. Location in patent: Page/Page column 13
[3] Patent: US2010/210852, 2010, A1. Location in patent: Page/Page column 5
[4] Patent: WO2009/7986, 2009, A1. Location in patent: Page/Page column 14
[5] Patent: WO2009/7986, 2009, A1. Location in patent: Page/Page column 14 |
|
|